1. Safety and early treatment effects of the CXCR2 antagonist SB in patients with cystic fibrosis 
Richard B. Moss, Sunil J. Mistry, Michael W. Konstan, Joseph M. Pilewski, Eitan Kerem, Ruth Tal-Singer, Aili L. Lazaar 
Journal of Cystic Fibrosis 
Volume 12, Issue 3, Pages (May 2013)
DOI: /j.jcf
Copyright © 2012 European Cystic Fibrosis Society. Terms and Conditions

2. Fig. 1
Study schematic.
Journal of Cystic Fibrosis  , DOI: ( /j.jcf )
Copyright © 2012 European Cystic Fibrosis Society. Terms and Conditions

3. Fig. 2
The effect of SB on sputum biomarkers at Day 28. Left: adjusted geometric mean±90% CI of the ratio to baseline for neutrophil numbers (top), neutrophil elastase (middle) and myeloperoxidase (bottom). —placebo, —SB mg, —SB mg. Right: adjusted geometric mean±90% CI for treatment ratio to placebo for SB mg () and SB mg ().
Journal of Cystic Fibrosis  , DOI: ( /j.jcf )
Copyright © 2012 European Cystic Fibrosis Society. Terms and Conditions

4. Fig. 3
The effect of SB on blood biomarkers at Day 14 and Day 28. Left: adjusted geometric mean±90% CI of the ratio to baseline for fibrinogen (top), C-reactive protein (middle) and CXCL8 (bottom). —placebo, —SB mg, —SB mg. Right: adjusted geometric mean±90% CI for treatment ratio to placebo for SB mg () and SB mg ().
Journal of Cystic Fibrosis  , DOI: ( /j.jcf )
Copyright © 2012 European Cystic Fibrosis Society. Terms and Conditions